Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 463-467

  Cong, Mian Er ^a   Mitchell, James ^a   Sweeney, Elizabeth ^a   Bachman, Shanon ^a   Hanson, Debra L ^a   Heneine, Walid ^a   García Lerma, J Gerardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

emtricitabine; HIV 1 drug resistance; Preexposure prophylaxis; tenofovir disoproxil fumarate

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE MUTATION; INFECTION PREVENTION; INFECTION RISK; K65R GENE; LENTIVIRINAE; LENTIVIRUS INFECTION; NONHUMAN; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EMTRICITABINE; HIV-1 DRUG RESISTANCE; PREEXPOSURE PROPHYLAXIS; TENOFOVIR DISOPROXIL FUMARATE;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; DEOXYCYTIDINE; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; HIV; MACACA; MUTATION, MISSENSE; ORGANOPHOSPHONATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84880244510     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit189     Document Type: Article

References (16)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 10.1056/NEJMoa1108524. 367:399-410.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylax-is for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preex-posure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; (10.1056/NEJMoa1110711). 367:423-34.
4. Food and Drug Administration. FDA approves first medication to reduce HIV risk. 16 July 2012. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm311821. htm. Accessed 10 May 2013.
5. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14:17-27.
6. Cong ME, Youngpairoj AS, Zheng Q, et al. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol 2011; 85:7933-6.
7. García-Lerma JG, Cong M, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macques form rectal SHIV infection. Sci Transl Med 2010; 2:14ra4.
8. Cong M, Youngpairoj AS, Aung WS, et al. Generation and mucosal transmissibility of emtricitabine-and tenofovir-resistant SHIV162p3 mutants in macaques. Virology 2011; 412:435-40.
9. Jennison C, Turnbull BW. Statistical approaches to interim monitoring of medical trials: a review and commentary. Statistical Sci 1990; 5:299-317.
10. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-99.
11. Cheung PK, Wynhoven B, Harrigan PR. 2004: Which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004; 6:107-16.
12. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofo-vir-containing first-line regimen. AIDS 2012; 26:1679-84.
13. Hamers RL, Sigaloff KC, Wensing AM, et al. PAStER. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-9.
14. van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74:1767-74.
15. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
16. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.